SM 2275
Alternative Names: SM-2275Latest Information Update: 06 May 2024
At a glance
- Originator Beijing StarMab BioMed Technology
- Class Antineoplastics; Immunotherapies; Single-domain antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral) prior to April 2024 (Beijing StarMab Biomed Technology pipeline, April 2024)
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical studies in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)